Submission Details
| 510(k) Number | K200230 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 30, 2020 |
| Decision Date | August 26, 2021 |
| Days to Decision | 574 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
K200230 is an FDA 510(k) clearance for the Aptiva Celiac Disease IgG Reagent, a Autoantibodies, Endomysial(tissue Transglutaminase) (Class II — Special Controls, product code MVM), submitted by Inova Diagnostics, Inc. (San Diego, US). The FDA issued a Cleared decision on August 26, 2021, 574 days after receiving the submission on January 30, 2020. This device falls under the Immunology review panel. Regulated under 21 CFR 866.5660.
| 510(k) Number | K200230 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 30, 2020 |
| Decision Date | August 26, 2021 |
| Days to Decision | 574 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
| Product Code | MVM — Autoantibodies, Endomysial(tissue Transglutaminase) |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.5660 |